NeoImmuneTech (NIT) is advancing NT-I7, the most clinically validated IL-7 candidate globally, designed to overcome the key limitations of CAR-T (including in-vivo CAR-T) and expand its reach for a broader adoption. NT-I7’s proprietary long-acting IL-7 fusion enhances T-cell expansion, persistence, infiltration, and stemness—driving potent anti-tumor activity and improved survival. Phase 1 clinical data in lymphoma show high response rates with durable benefit with no CAR-T–related CRS/ICANS signals.